Outsmarting cancer
to deliver more cures

  • CARGO Therapeutics to Present at the Jefferies Global Healthcare Conference

    SAN MATEO, Calif., May 31, 2023 – CARGO Therapeutics, Inc. (CARGO), a biotechnology company advancing a next generation of CAR T-cell therapies for cancer, today announced that management will present at the upcoming Jefferies Global Healthcare Conference on Friday, June 9, 2023 at 9:00 a.m. Eastern Time in New York City. CARGO is advancing an autologous CD22 chimeric antigen receptor […]

    Read More

  • CARGO Therapeutics Raises $200 Million in Oversubscribed, Upsized Series A Financing to Advance its Pipeline of Next Generation CAR T-Cell Therapies

    – Series A financing co-led by Third Rock Ventures, RTW and Perceptive Xontogeny Venture Fund, and includes new investors Nextech, Janus Henderson Investors, Ally Bridge Group, Wellington Management, T. Rowe Price, Cormorant Asset Management and Piper Heartland with participation from existing seed investors – – Initial Phase 1 results with CARGO’s CD22 CAR T-cell therapy […]

    Read More